401 related articles for article (PubMed ID: 22928736)
1. Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.
Kwarcinski FE; Fox CC; Steffey ME; Soellner MB
ACS Chem Biol; 2012 Nov; 7(11):1910-7. PubMed ID: 22928736
[TBL] [Abstract][Full Text] [Related]
2. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
Johnson TK; Soellner MB
Bioconjug Chem; 2016 Jul; 27(7):1745-9. PubMed ID: 27266260
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.
Du G; Rao S; Gurbani D; Henning NJ; Jiang J; Che J; Yang A; Ficarro SB; Marto JA; Aguirre AJ; Sorger PK; Westover KD; Zhang T; Gray NS
J Med Chem; 2020 Feb; 63(4):1624-1641. PubMed ID: 31935084
[TBL] [Abstract][Full Text] [Related]
4. Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
Fu T; Zuo Y; Zhong Z; Chen X; Pan Z
Eur J Med Chem; 2022 Feb; 229():114051. PubMed ID: 34952433
[TBL] [Abstract][Full Text] [Related]
5. Exquisitely specific bisubstrate inhibitors of c-Src kinase.
Brandvold KR; Santos SM; Breen ME; Lachacz EJ; Steffey ME; Soellner MB
ACS Chem Biol; 2015 Jun; 10(6):1387-91. PubMed ID: 25793938
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.
Gushwa NN; Kang S; Chen J; Taunton J
J Am Chem Soc; 2012 Dec; 134(50):20214-7. PubMed ID: 23190395
[TBL] [Abstract][Full Text] [Related]
7. Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors.
Breen ME; Steffey ME; Lachacz EJ; Kwarcinski FE; Fox CC; Soellner MB
Angew Chem Int Ed Engl; 2014 Jul; 53(27):7010-3. PubMed ID: 24797781
[TBL] [Abstract][Full Text] [Related]
8. Development of a highly selective c-Src kinase inhibitor.
Brandvold KR; Steffey ME; Fox CC; Soellner MB
ACS Chem Biol; 2012 Aug; 7(8):1393-8. PubMed ID: 22594480
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy.
Hah JM; Sharma V; Li H; Lawrence DS
J Am Chem Soc; 2006 May; 128(18):5996-7. PubMed ID: 16669643
[TBL] [Abstract][Full Text] [Related]
10. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
[TBL] [Abstract][Full Text] [Related]
11. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
12. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
13. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Moroco JA; Baumgartner MP; Rust HL; Choi HG; Hur W; Gray NS; Camacho CJ; Smithgall TE
Chem Biol Drug Des; 2015 Aug; 86(2):144-55. PubMed ID: 25376742
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo M; Dai S; Wu D; Duan Y; Li J; Qu L; Jiang L; Chen Z; Chen X; Chen Y
Bioorg Med Chem Lett; 2021 Feb; 34():127757. PubMed ID: 33359446
[TBL] [Abstract][Full Text] [Related]
15. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
Hill ZB; Perera BG; Maly DJ
Mol Biosyst; 2011 Feb; 7(2):447-56. PubMed ID: 21060940
[TBL] [Abstract][Full Text] [Related]
16. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
Lin YL; Meng Y; Huang L; Roux B
J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
[TBL] [Abstract][Full Text] [Related]
17. Chemical genetic strategy for targeting protein kinases based on covalent complementarity.
Garske AL; Peters U; Cortesi AT; Perez JL; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15046-52. PubMed ID: 21852571
[TBL] [Abstract][Full Text] [Related]
18. Reduced efficacy of a Src kinase inhibitor in crowded protein solution.
Kasahara K; Re S; Nawrocki G; Oshima H; Mishima-Tsumagari C; Miyata-Yabuki Y; Kukimoto-Niino M; Yu I; Shirouzu M; Feig M; Sugita Y
Nat Commun; 2021 Jul; 12(1):4099. PubMed ID: 34215742
[TBL] [Abstract][Full Text] [Related]
19. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
20. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
